ABSTRACT
First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Talia Nasr is first author on ‘Disruption of a Hedgehog-Foxf1-Rspo2 signaling axis leads to tracheomalacia and a loss of Sox9+ tracheal chondrocytes’, published in DMM. Talia is a MD/PhD student at the University of Cincinnati, USA, currently in the final two MD years, with the PhD work completed in the lab of Aaron Zorn, investigating the pathogenesis of congenital tracheoesophageal defects.
Talia Nasr
How would you explain the main findings of your paper to non-scientific family and friends?
Development of tracheal cartilage, which helps maintain an open airway, requires the protein Sox9. Our paper finds a time-specific role for the Hedgehog signalling pathway and the protein Foxf1, a Hedgehog target, to support Sox9 in the trachea. This work also reveals a potential signalling mechanism for tracheal cartilage development that involves Hedgehog, Foxf1, the Wnt signalling pathway and Sox9. Ultimately, these results show potential ways in which congenital defects in human tracheal chondrogenesis might develop.
What are the potential implications of these results for your field of research?
These results suggest that Hedgehog and Wnt signalling in the trachea are fairly intertwined, and warrant a deeper dive into how these two pathways interact, considering that they're both required for tracheal development. These results also lead to more questions about the specific targets of Foxf1 during tracheal development. They really make me wonder whether Foxf1 might directly bind to some unexpected genes that have been previously implicated in human congenital tracheal defects.
What are the main advantages and drawbacks of the model system you have used as it relates to the disease you are investigating?
Mouse tracheal patterning appears to be quite similar to that of humans, so mice can be used to model human tracheal cartilage defects. Mouse genetics, though, can be complicated and require significant time to properly set up and support.
What has surprised you the most while conducting your research?
I was continually amazed at the time-specific roles for Hedgehog and Foxf1 that our results showed. For example, early Cre-mediated deletion of Foxf1 led to a single foregut tube, whereas Cre-mediated deletion starting just about a day later didn't seem to have any significant impact on tracheoesophageal separation at all. An embryo's integration of so many moving parts during development, especially in such a small timeframe, is always so impressive to me.
“An embryo's integration of so many moving parts during development, especially in such a small timeframe, is always so impressive to me.”
Describe what you think is the most significant challenge impacting your research at this time and how will this be addressed over the next 10 years?
COVID-19 has really significantly disrupted how everyone does research, and I think we're all going to be continually figuring out what is our ‘new normal’ for doing science, and life in general, for a long time to come.
A developing mouse oesophagus and trachea during differentiation of smooth muscle and cartilage lineages.
What changes do you think could improve the professional lives of early-career scientists?
I think continuing discussions and implementing changes to foster, recruit and support a diverse academia is a good place to start. I also always find it helpful to learn more about the actual business of running a lab, as I don't think that gets openly discussed enough with trainees who are considering careers in academia.
What's next for you?
I'm currently completing the MD portion of my combined MD/PhD degree with the goal of eventually entering a paediatric residency program that integrates research with clinical training.
Footnotes
Talia Nasr's contact details: Center for Stem Cell and Organoid Medicine, Division of Developmental Biology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
E-mail: talia.nasr{at}cchmc.org
- © 2021. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Reference
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
The twin pillars of Disease Models & Mechanisms
In her first Editorial as Editor-in-Chief, Liz Patton sets out her vision and priorities for DMM focusing on four thematic challenges: mechanisms of disease, innovative technologies, disease progression through time and therapy.
Extended deadline - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway.
Find out more about the issue and how to submit your manuscript.
Perspective - Modelling the developmental origins of paediatric cancer to improve patient outcomes
James Amatruda authors our first Perspective, discussing some of the key challenges in paediatric cancer from his perspective as a physician-scientist.
A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities
In this issue’s Editor’s choice, Ketan Patel and colleagues describe how even brief exposure to muscle-growth-promoting treatments exerts a long-term detrimental effect on the testes, and test promising therapeutics to mitigate this side-effect.